The National Comprehensive Cancer Network and the American Society of Clinical Oncology guidelines on the use of white blood cell growth factors both state that in patients receiving chemotherapy regimens with a 10–20% risk of FN, additional risk factors (e.g., age ≥ 65 years, a decreased performance status, a history of FN, and comorbidities, including renal or liver dysfunction) need to be considered for G-CSF therapy [26, 27], most of which have been confirmed as independent risk factors for neutropenic complications in the risk model developed by Lyman et al. [28]. This evidence concerns the gene CSF3 and Decreased liver function.